Jonas Wang, PhD

Chairman

Over 40 years in pharmaceutical research, drug delivery innovation, and life science leadership. From the Johnson Medal at J&J to building a global cord blood therapeutics company.

Johnson Medal (J&J) 30+ Patents 2,300+ Transplants

Background

From pharmaceutical R&D to saving lives

Dr. Jonas Wang began his career in pharmaceutical science, earning a PhD in Physical Pharmacy from the University of Iowa after completing his pharmacy degree at the National Defense Medical Center in Taiwan. His early career took him to Bristol-Myers Squibb, where he served as Associate Director of Basic Pharmaceutics, before joining Johnson & Johnson.

At J&J, Dr. Wang rose to Vice President of Research and Technology for Consumer Products and Corporate Director of the Drug Delivery Technology Resource Center. He was responsible for new product technology, patent strategy, and competitive intelligence across J&J's skin and hair care franchise. During his tenure, he developed more than 10 core technologies and filed over 30 patents. His invention of a breakthrough anti-wrinkle cream technology earned him the Johnson Medal, the highest technical achievement award at Johnson & Johnson.

After J&J, Dr. Wang joined Sycamore Management Corporation as a partner specializing in life sciences and biotechnology investments. In 2009, he brought his deep scientific expertise and business acumen to StemCyte, where he has served as Chairman and CEO, guiding the company's growth in cord blood banking and regenerative cell therapy.

Under Dr. Wang's leadership, StemCyte has shipped more than 2,300 cord blood units to over 325 transplant centers across 40 countries, establishing a globally recognized cord blood inventory. He has also driven the company's expansion into regenerative medicine, overseeing the development of REGENECYTE® and securing FDA biologics licensure, advancing StemCyte's position in cell-based therapeutics.

"At J&J, I strove to invent the best anti-wrinkle technologies, which contributed to making millions of women feel more beautiful and confident. But as the holder of a PhD in pharmacy, my personal goal has always been to save lives."

Jonas Wang, PhD — Chairman, StemCyte

Defining achievements

30+

Patents Filed

Drug delivery and pharmaceutical technologies at Johnson & Johnson

2,300+

Transplants Worldwide

Cord blood units shipped to 325+ hospitals in 40 countries

Johnson Medal

Highest technical achievement award at Johnson & Johnson

Career

Professional journey

Education

National Defense Medical Center, Taiwan & University of Iowa

Earned a pharmacy degree from the National Defense Medical Center in Taipei, then a PhD in Physical Pharmacy from the University of Iowa, laying the scientific foundation for a career spanning drug delivery, pharmaceutical innovation, and life science leadership.

Bristol-Myers Squibb

Associate Director, Basic Pharmaceutics

Joined the Pharmaceutical Research Institute at Bristol-Myers Squibb, where he advanced drug formulation and delivery technologies as part of the company's core R&D operation.

Johnson & Johnson

VP of Research & Corporate Director, Drug Delivery

Rose to Vice President of Research and Technology at J&J Consumer Products and Corporate Director of the Drug Delivery Technology Resource Center. Responsible for new product technology, patent strategy, competitive intelligence, and measurement methodology across J&J's skin and hair care franchise.

Johnson Medal

Highest technical achievement award at J&J

Received the Johnson Medal, the most prestigious technical honor at Johnson & Johnson, for inventing one of the company's breakthrough anti-wrinkle cream technologies. During his J&J tenure, developed more than 10 core technologies and filed over 30 patents.

Sycamore Ventures

Partner, Life Sciences & Biotech Investments

Joined Sycamore Management Corporation in Princeton, New Jersey, as a partner focused on life sciences and biotechnology investments. Served on J&J Consumer Product Worldwide's Licensing & Acquisition Committee and was a key driver of several major acquisitions.

2009

Joins StemCyte

Joined StemCyte as COO, bringing decades of pharmaceutical R&D leadership and business development experience to a company that was expanding its global reach in cord blood banking and regenerative medicine.

2011

Chairman & CEO, StemCyte

Became Chairman and CEO, setting the strategic vision for StemCyte's dual-track approach: strengthening core banking services while advancing clinical development of regenerative cell therapies.

Today

Chairman, StemCyte International

Leads StemCyte International (TPEX: 4178) as Chairman, overseeing operations across the United States and Taiwan. Under his leadership, StemCyte has shipped 2,300+ transplant units to 325+ hospitals in 40 countries and secured FDA BLA approval for REGENECYTE®.

Education